RxDoctor Payments Data

William Simpson, MD

Gastroenterology · Kalispell, MTNPI 1487655346

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,097 of the $1,591 with a category attached, or 69.0%. 12 manufacturers reported payments, led by Boston Scientific at 30.7% of the total. Reporting peaked in 2019 at $1,137 and has fallen 89.4% since, to $121 in 2025.

$1,591in general payments, 2019–2025

Across 66 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$488
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$240
  • AbbVie$234
  • Gilead$180
  • E.r. Squibb & Sons, L.L.C.$115
  • Intercept Pharmaceuticals, Inc.$102
  • plus $231 from 6 others

What the payments were for

  • Travel & lodging$48831%
  • Food & beverage$1,09769%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,591 in reported general payments places this provider in the 70th percentile of 34 gastroenterology providers in Montana.

See all gastroenterology providers in Montana

Medicare billing

Part B allowed, 2024
$122,216
Medicare patients
593
Services billed
977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab18$221,531
XifaxanRifaximin25$79,279
Pantoprazole Sodium758$7,094
Budesonide DrBudesonide24$5,564
Mesalamine ErMesalamine16$5,211
Esomeprazole Magnesium70$2,290
Colestipol Hcl28$1,567
Budesonide EcBudesonide11$1,465
Bethanechol Chloride29$1,303
ConstuloseLactulose13$1,137
Famotidine57$576
Lactulose16$553
Omeprazole48$544
Spironolactone33$350
Carvedilol50$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$240$79,27925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 34 gastroenterology providers in Montana.

Other gastroenterology in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →